Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

Gastroenterology

Volumn 154, Issue 4, 2018, Pages 976-988.e4

  Dietz, Julia ^a   Susser, Simone ^a   Vermehren, Johannes ^a   Peiffer, Kai Henrik ^a   Grammatikos, Georgios ^a   Berger, Annemarie ^a   Ferenci, Peter ^b   Buti, Maria ^c   Müllhaupt, Beat ^d   Hunyady, Bela ^e   Hinrichsen, Holger ^f   Mauss, Stefan ^g   Petersen, Jörg ^h   Buggisch, Peter ^h   Felten, Gisela ⁱ   Hüppe, Dietrich ⁱ   Knecht, Gaby ^j   Lutz, Thomas ^j   Schott, Eckart ^k   Berg, Christoph ^l   Spengler, Ulrich ^m   von Hahn, Thomas ⁿ   Berg, Thomas ^o   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a,p   Antoni, C ^q   Vogelmann, R ^q   Ebert, M ^q   Backhus, J ^q   Seufferlein, T ^q   Balavoine, J ^q   Giostra, E ^q   Berg, C ^q   Cornberg, M ^q   Wedemeyer, H ^q   Manns, M ^q   De Gottardi, A ^q   Esteban, R ^q   Discher, T ^q   Roeb, E ^q   Gress, M ^q   Gunther R ^q   Wietzke Braun, P ^q   Herrmann, A ^q   Stallmach, A ^q   Hoffmann, D ^q   Klinker, H ^q   Kodal, A ^q   Lammert, F ^q   Lobermann M ^q   Schulze zur Wiesch, J ^q   von Felden, J ^q   Piecha, F ^q   Lohse, A ^q   Gotze T ^q   Malfertheiner, P ^q   Mayerle, J ^q   Moradpour, D ^q   Moreno, C ^q   Neumann Haefelin, C ^q   Thimme, R ^q   Reinhardt, L ^q   Ellenrieder, V ^q   Schattenberg, J ^q   Sprinzl, M ^q   Galle, P ^q   Schmidt, J ^q   Schott, E ^q   Epple, H J ^q   Siebler, J ^q   Stauber, R ^q   Steckstor, M ^q   Schmiegel, W ^q   Stremmel, W ^q   Strey, B ^q   Tomasiewicz, K ^q   Trautwein, C ^q   Zachoval, R ^q   Angeli, W ^q   Beckebaum, S ^q   Doberauer, C ^q   Ende, K ^q   Erhardt, A ^q   Garrido Luneburg A ^q   Gattringer, H ^q   Genne D ^q   Gschwantler, M ^q   Gundling, F ^q   Hartmann, C ^q   Heyer, T ^q   Hirschi, C ^q   Kanzler, S ^q   Kordecki, N ^q   Kraus, M ^q   Kullig, U ^q   Magenta, L ^q   Terziroli Beretta Piccoli, B ^q   Menges, M ^q   Mohr, L ^q   Muehlenberg, K ^q   Niederau, C ^q   Paulweber, B ^q   Petrides, A ^q   Piso, R ^q   Rambach, W ^q   Reiser, M ^q   Riecken, B ^q   Roth, J ^q   Schofl R ^q   Maieron, A ^q   Schneider, A ^q   Schuchmann, M ^q   Schulten Baumer, U ^q   Seelhoff, A ^q   Semela, D ^q   Stich, A ^q   Vollmer, C ^q   Bruckner J ^q   Ungemach, J ^q   Walter, E ^q   Weber, A ^q   Winzer, T ^q   Abels, W ^q   Adler, M ^q   Audebert, F ^q   Baermann, C ^q   Bastlein E ^q   Barth, R ^q   Barthel, K ^q   Baumgartl, K ^q   Becker, W ^q   Benninger, J ^q   Beyer, T ^q   Bodtlander A ^q   Bohm G ^q   Bohr, U ^q   Moll, A ^q   Naumann, U ^q   Borner N ^q   Bruch, H R ^q   Busch, N ^q   Burkhard, O ^q   Chirca, C ^q   Dienethal, A ^q   Dietel, P ^q   Dreher, F ^q   Efken, P ^q   Ehrle, U ^q   Emke, F ^q   Fischer, J ^q   Fischer, U ^q   Frederking, D ^q   Frick, B ^q   Gantke B, B ^q   Geyer, P ^q   Glaunsinger, T ^q   Goebel, F ^q   Gobel U ^q   Graf, R ^q   Herder, M ^q   Heuchel, T ^q   Heuer, S ^q   Heyne, R ^q   Hoffl K H ^q   Hofmann, W P ^q   Holst, F ^q   Horster H ^q   John, C ^q   Jung, M C ^q   Kallinowski, B ^q   Kerzel, W ^q   Khaykin, P ^q   Klarhof, M ^q   Knapp, B ^q   Knevels, U ^q   Korfer A ^q   Koster A ^q   Kunzig B ^q   Langenkamp, A ^q   Kuhn, M ^q   Littman, M ^q   Lohr H ^q   Ludwig, L ^q   Lutz, U ^q   Maurer, P ^q   Mayer, C ^q   Meister, V ^q   Moritzen, D ^q   Mross M ^q   Mundlos, M ^q   Nehls, O ^q   Ningel, K ^q   Oelmann, A ^q   Olejnik, H ^q   Pascher, E ^q   Philipp, A ^q   Pichler, M ^q   Polzien, F ^q   Raddant, R ^q   Riedel, M ^q   Rietzler, S ^q   Rump, A ^q   Schmidt, W ^q   Schmidtler von Fabris, J ^q   Schneider, L ^q   Schober, A ^q   Schwenzer, J ^q   Seidel, T ^q   Seitel, G ^q   Sick, C ^q   Simon, K ^q   Stahler D ^q   Steffens, H ^q   Svensson, K ^q   Tacke, W ^q   Teubner, K ^q   Thieringer, J ^q   Trappe, U ^q   Ullrich, J ^q   Usadel, S ^q   von Lucadou, A ^q   Werheid Dobers, M ^q   Zehnter, E ^q   Zipf, A ^q   more..

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Kaposi Mor Teaching Hospital   (Hungary)

^f Gastroenterology Gastroenterologische Schwerpunkt Praxis   (Germany)

^g Division of Gastroenterology   (Germany)

^h Ifi Institute for Interdisciplinary Medicine   (Germany)

ⁱ Practice of Hepatology   (Germany)

^j Infektiologikum   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m UNIVERSITY OF BONN   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^p ST JOSEFS HOSPITAL   (Germany)

^q NONE

more..

Author keywords

DAA; HCV; RASs; Virologic Treatment Failure

Indexed keywords

DACLATASVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRAL PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; RETREATMENT; SALVAGE THERAPY; SUSTAINED VIROLOGIC RESPONSE; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SUBSTITUTION; ENZYMOLOGY; EUROPE; GENETICS; GENOTYPE; HEPACIVIRUS; METABOLISM; MULTICENTER STUDY; PHENOTYPE; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT FAILURE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PHENOTYPE; PROTEASE INHIBITORS; RETREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85043229335     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.11.007     Document Type: Article

References (59)

1. Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64 (2016), 486–504.
2. Gower, E., Estes, C., Blach, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
3. Pawlotsky, J.M., Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151 (2016), 70–86.
4. Lawitz, E., Flamm, S., Yang, J.C., et al. Retreatment of patients who failed 8 or 12 weeks of Ledipasvir/Sofosbuvir-based regimens with Ledipasvir/Sofosbuvir for 24 weeks. J Hepatol, 62, 2015, S192.
5. EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
6. Gane, E.J., Stedman, C.A., Hyland, R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368 (2013), 34–44.
7. Wyles, D., Dvory-Sobol, H., Svarovskaia, E.S., et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol 66 (2017), 703–710.
8. Gane, E.J., Hyland, R.H., An, D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461.e1.
9. Kwo, P., Gitlin, N., Nahass, R., et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64 (2016), 370–380.
10. Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64 (2016), 360–369.
11. Lawitz, E., Sulkowski, M.S., Ghalib, R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
12. Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151 (2016), 501–512.e1.
13. Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
14. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
15. Poordad, F., Schiff, E.R., Vierling, J.M., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
16. Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370 (2014), 1983–1992.
17. Feld, J.J., Kowdley, K.V., Coakley, E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1594–1603.
18. Zeuzem, S., Jacobson, I.M., Baykal, T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1604–1614.
19. Susser, S., Dietz, J., Schlevogt, B., et al. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. J Hepatol 67 (2017), 680–686.
20. Dietz, J., Susser, S., Berkowski, C., et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS One, 10, 2015, e0134395.
21. Bartels, D.J., Sullivan, J.C., Zhang, E.Z., et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87 (2013), 1544–1553.
22. Tong, X., Le Pogam, S., Li, L., et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 209 (2014), 668–675.
23. Svarovskaia, E.S., Dvory-Sobol, H., Parkin, N., et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 59 (2014), 1666–1674.
24. Gane, E.J., Abergel, A., Metivier, S., et al. The emergence of NS5B resistant associated variant S282T after sofosbuvir-based treatment. Hepatology, 62, 2015, 322A.
25. Svarovskaia, E.S., Dvory-Sobol, H., Doehle, B., et al. L159F and V321A sofosbuvir treatment-emergent HCV NS5B substitutions. Hepatology, 60, 2014, 218A.
26. Donaldson, E.F., Harrington, P.R., O'Rear, J.J., et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61 (2015), 56–65.
27. Di Maio, V.C., Cento, V., Lenci, I., et al. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies. J Hepatol 66 (2017), S82–S83.
28. Zeuzem, S., Flamm, S., Tong, M., et al. A randomized, controlled, phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir or sofosbuvir/velpatasvir for 12 weeks in direct acting antiviral-experienced patients with genotype 1–6 HCV infection: the POLARIS-4 study. Hepatology, 64, 2016, 59A.
29. Lenz, O., Verbinnen, T., Fevery, B., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 62 (2015), 1008–1014.
30. Fevery, B., Verbinnen, T., Peeters, M., et al. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study. J Viral Hepat 24 (2017), 28–36.
31. Sulkowski, M.S., Vargas, H.E., Di Bisceglie, A.M., et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150 (2016), 419–429.
32. Bourlière, M., Gordon, S.C., Ramji, A., et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1–6 infection: the phase 3 POLARIS-1 study. Hepatology, 64, 2016, 102A.
33. Poordad, F., Pol, S., Asatryan, A., et al. MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure. J Hepatol 66 (2017), S83–S84.
34. Pilot-Matias, T., Krishnan, P., Schnell, G., et al. Resistance analysis in the MAGELLAN-1 study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors. J Hepatol 66 (2017), S708–S709.
35. Bourliere, M., Gordon, S.C., Flamm, S.L., et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (2017), 2134–2146.
36. de Ledinghen, V., Laforest, C., Hezode, C., et al. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE study. Clin Infect Dis, 2017 Epub ahead of print.
37. Vermehren, J., Susser, S., Dietz, J., et al. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J Hepatol, 64, 2016, S188.
38. Hezode, C., Chevaliez, S., Scoazec, G., et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology 63 (2016), 1809–1816.
39. Chevaliez, S., Trimoulet, P., Dorival, C., et al. Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER). J Hepatol, 66, 2017, S84.
40. Cheng, G., Tian, Y., Doehle, B., et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 60 (2016), 1847–1853.
41. Gane, E.J., Kowdley, K.V., Pound, D., et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis c virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology 151 (2016), 902–909.
42. Sarrazin, C., Cooper, C., Manns, M., et al. No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies. J Hepatol, 66, 2017, S299.
43. Krishnan, P., Schnell, G., Tripathi, R., et al. Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. J Hepatol, 66, 2017, S500.
44. Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
45. Vermehren, J., Dietz, J., Peiffer, K.H., et al. High sustained virologic response rates in HCV genotype 3 patients with and without cirrhosis treated with daclatasvir/sofosbuvir or velpatasvir/sofosbuvir ± ribavirin according to baseline resistance analysis. J Hepatol, 66, 2017, S83.
46. Krishnan, P., Tripathi, R., Schnell, G., et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 59 (2015), 5445–5454.
47. Krishnan, P., Tripathi, R., Schnell, G., et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology 60 (2014), 1134A–1135A.
48. Schnell, G., Tripathi, R., Beyer, J., et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 59 (2015), 6807–6815.
49. Hezode, C., Asselah, T., Reddy, K.R., et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385 (2015), 2502–2509.
50. Di Maio, V.C., Cento, V., Lenci, I., et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int 37 (2017), 514–528.
51. Poordad, F., Bennett, M., Sepe, T.E., et al. Ombitasvir/paritaprevir/r, dasabuvir, and sofosbuvir treatment of patients with HCV genotype 1-infection who failed a prior course of DAA therapy: the Quartz-I study. J Hepatol 64 (2016), S767–S768.
52. Svarovskaia, E.S., Gane, E., Dvory-Sobol, H., et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213 (2016), 1240–1247.
53. Lenz, O., Verbinnen, T., Lin, T.I., et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54 (2010), 1878–1887.
54. Fridell, R.A., Wang, C., Sun, J.H., et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54 (2011), 1924–1935.
55. Zhou, N., Hernandez, D., Ueland, J., et al. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. J Infect Dis 213 (2016), 206–215.
56. Hernandez, D., Zhou, N., Ueland, J., et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 57 (2013), 13–18.
57. Pilot-Matias, T., Tripathi, R., Cohen, D., et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59 (2015), 988–997.
58. Krishnan, P., Beyer, J., Mistry, N., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59 (2015), 979–987.
59. Kati, W., Koev, G., Irvin, M., et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59 (2015), 1505–1511.